COO

Business profile & competitive position

The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California, classified under the Healthcare sector in the Medical - Instruments & Supplies industry. It operates through two segments: CooperVision, which develops, manufactures and markets contact lenses spanning silicone hydrogel, myopia management, orthokeratology and scleral lenses; and CooperSurgical, which offers more than 600 products and services focused on fertility and women’s health. A 13.5% net margin and a 6.9% return on equity describe the economics of the business. The margin captures recurring, brand-driven demand for lenses and specialty devices, while the modest ROE reflects the capital absorbed by a global manufacturing footprint, two-segment R&D and roughly 500 research-and-development employees. Products are sold in over 130 countries and positively impact more than fifty million lives each year. MiSight 1 day is the only contact lens approved by the FDA, Chinese NMPA and Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children.

Financial posture

Cooper carries a market capitalization of $10.8 billion and a P/E ratio of 18.9, placing it at roughly nineteen times earnings against a 13.5% net margin and 6.9% ROE. The 13.5% margin reflects stable demand for vision care and fertility products, while the 6.9% ROE points to the capital intensity of running two global franchises. A beta of 0.82 implies the stock has historically moved with less volatility than the broader market, consistent with the defensive, consumption-linked nature of contact lenses and fertility services. The current snapshot shows the stock at $55.38, an RSI of 30.3 and a 50-day exponential moving average of $64.98, meaning price sits materially below its recent trend and the RSI is near the traditional oversold threshold.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines four near-term operational priorities. CooperVision is focused on greater worldwide market penetration of recently introduced products and expanding its presence in both existing and emerging markets. To support that growth, CooperVision is increasing investment in distribution and packaging capabilities. Separately, it is investing to develop the myopia management market by educating eye care practitioners, patients and their families, a push anchored by the MiSight 1 day platform. On the CooperSurgical side, the company expects to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health. The common thread is revenue growth funded by internal investment and tuck-in M&A rather than a restructuring of either segment.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies business, Cooper carries the macro fingerprints typical of global med-tech. Contact lenses and fertility devices are regulated medical products, so decisions by the FDA, Chinese NMPA, Japanese MHLW and other national health agencies influence what can be sold and how it can be marketed. Currency risk is material because products are sold in over 130 countries; a stronger U.S. dollar compresses reported overseas revenue and margins. Supply-chain exposure sits in raw materials and precision-manufacturing inputs used in silicone hydrogel lenses and surgical devices. Trade policy, including tariffs on medical goods and components, can alter landing costs. Demand is tied to healthcare utilization, discretionary fertility spending, and demographic trends such as the rising incidence of childhood myopia. These are industry-level forces; the company mitigates them through geographic diversification rather than immunity.

Recent developments

Recent headlines under the COO ticker have been a mix of company-specific legal alerts and unrelated executive-trading news. On September 26, 2026, fool.com reported that an AST SpaceMobile COO sold 12,000 shares for $707,000 amid a 47% one-year return. On September 24, 2026, fool.com separately reported that Bloom Energy COO Chitoori Satish S sold shares for $775,072. Neither item concerns The Cooper Companies directly; they appear to be cross-ticker noise generated by the “COO” job-title keyword. More relevant to the company, two investor-alert press releases appeared: on September 25, 2026, globenewswire.com carried a Rosen Law Firm notice encouraging investors who suffered losses in The Cooper Companies to contact the firm, and on September 24, 2026, prnewswire.com published a Pomerantz Law Firm investigation into claims on behalf of Cooper Companies investors. These releases do not specify outcomes, but they contribute to near-term sentiment around the name.

Earnings behavior & post-earnings drift

Cooper’s earnings record is technically flawless over the last eight reported quarters: the company beat the consensus estimate in all eight, with an average surprise of 4.2%. Yet the post-earnings price path has not rewarded that consistency. The average five-day move after earnings across those eight quarters is -2.34%, classified as a downward drift. The most recent four quarters show why a beat does not guarantee a rally. On September 9, 2026, Cooper reported $1.15 EPS against a $1.12 estimate, a 2.7% beat, but the stock fell 14.67% the next day and 13.97% over the following five sessions. On June 4, 2026, a 10% beat on $1.21 versus $1.10 produced a strong positive reaction, up 8.58% the next day and 8.85% over five days. On March 5, 2026, a 6.8% beat on $1.10 versus $1.03 was met with a -4.55% one-day drop and -10.82% over five days. And on December 4, 2025, a 3.6% beat on $1.15 versus $1.11 produced a 5.67% one-day pop and 6.59% over five days. Bulls and bears are extracting different messages from the same beats, and the market’s real expectation appears to be set by forward guidance, margin commentary and segment mix rather than the headline EPS number alone. The next report is scheduled for December 3, 2026, after the close, with the consensus EPS estimate at $1.08.

For a deeper dive into how institutional analysts currently view revenue trajectory, segment margins and the December 3, 2026 earnings setup, review the full institutional verdict on COO rather than relying on headlines alone.